HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

PCSK9 inhibitors on top of statins regressed plaque in GLAGOV and PRECISE-IVUS

Gokhan Can · Dec 25, 2023 · ♥ 7 reactions · 3 comments · original Facebook post
PCSK9, ezetimibe & newer drugsPlaque, CAC & CT angiography
AI summary & key facts

Summarizes IVUS trials of PCSK9 inhibition for plaque regression. In GLAGOV, adding evolocumab to statins significantly reduced percent atheroma volume versus statins alone, PRECISE-IVUS showed a similar direction, and ODYSSEY J-IVUS with alirocumab was a small, non-significant reduction over a short 36 weeks.

PCSK9 Inhibitors (Praluent or Repatha): Plaque Reduction

The GLAGOV trial (2016) demonstrated that the PCSK9 inhibitor evolocumab reduced total atheroma volume by 2.9%, as compared to a 0.4% reduction with placebo over a period of 76 weeks. Meanwhile, the ODYSSEY J-IVUS trial (2019) showed a slight but non-significant reduction in total atheroma volume with alirocumab over 36 weeks. These findings suggest that such agents may have significant benefits for plaque regression, highlighting the need for longer-term studies to fully demonstrate their efficacy.

Key numerical results:

##

PS: Facebook links stopped working recently. I have a longer blog post with links here:

mylongevityjourney.blogspot.comPlaque Reduction / CVDStatins - HELPFUL Multiple studies have indicated that statins can lead to atherosclerotic plaque regression, achieving a reduction in tot...mylongevityjourney.blogspot.com

Research cited

#statins#plaque#pcsk9#ivus#repatha
← newer: Statin studies on plaque regression, with a link to a longerolder: SELECT trial: semaglutide cut major cardiovascular events 20 →